Australia's most trusted
source of pharma news
Posted 2 April 2024 AM
A purportedly compounded version of Novo Nordisk's blockbuster weight loss drug semaglutide has allegedly resulted in the hospitalisation of a patient with peripheral neuropathy, prompting the TGA to issue an 'extreme caution' warning to consumers.
The regulator tested the product labelled Semaglutide 2.64mg/mL, L-carnitine 100mg/mL B12 .05mg/mL solution for SC injection 3 and found the vials contain ten times the amount of vitamin B12 (cyanocobalamin) labelled and the content of L-carnitine, was estimated at 0.5-0.7mg/mL, well below the labelled 100mg/mL.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.